Alzheimer's disease is a progressive neurological disorder that typically leads to a gradual decline in cognitive function, including memory loss, diminished thinking ability, and behavioral changes. This disease is generally age-related and is more prevalent among older adults, particularly those over 65.

 

In the brains of Alzheimer's patients, abnormal accumulation of Tau protein occurs, forming neurofibrillary tangles (NFTs). This abnormal aggregation disrupts the internal structure of neurons, impairs neuronal function and communication, and reduces patients' memory and cognitive abilities. Scientists have been exploring various methods to intervene in the abnormal aggregation of Tau protein to address Alzheimer's disease and other neurodegenerative disorders.

 

Recently, a research team led by Dr. Xiaolu Yang at the University of Pennsylvania discovered that TRIM11 plays a significant role in suppressing tau protein aggregation: TRIM11 binds to tau protein and reduces its levels; it prevents misfolding of tau protein; and it can dissolve pre-existing tau aggregates.

 

Special Statement:   This article is sourced from the official website of MingCeler Biotech. Personal sharing is permitted. However, media outlets or organizations are strictly prohibited from reprinting or republishing this content on any other platform without prior authorization. For reprint authorization or other cooperation inquiries, please contact: sales@mingceler.com.

Disclaimer:   Some materials used are sourced from the internet. If any infringement occurs, please contact us for removal. This article is intended for informational purposes only and does not constitute medical advice or provide treatment recommendations. The views expressed herein do not represent the official stance of MingCeler Biotech, nor do they imply Mingceler Biotech's endorsement or opposition to the opinions presented.